Search tips
Search criteria 


Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Neurol Neurosurg Psychiatry. 1981 May; 44(5): 426–429.
PMCID: PMC490987

Bromocriptine in Parkinson's disease: a study of cardiovascular effects.


Blood pressure and pulse rate were studied in 20 Parkinsonian patients on no treatment, and during treatment with bromocriptine (mean dosage 148 mg/day) as the sole anti-Parkinsonian therapy. The drug was shown to reduce erect systolic and diastolic and supine systolic blood pressure and to increase erect pulse rate, in a predictable dose-dependent manner. The occurrence of episodes of significant postural hypotension was less predictable and was a transitory phenomenon in all patients. Peripheral dopamine receptor blockade with domperidone did not alter the findings, suggesting that the principal mechanism for these cardiovascular effects is a central dopaminergic one.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (471K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Reid JL, Calne DB, George CF, Vakil SD. The action of L(-)-dopa on baroreflexes in Parkinsonism. Clin Sci. 1972 Dec;43(6):851–859. [PubMed]
  • Calne DB, Teychenne PF. L-DOPA effect on blood pressure in man. Prog Brain Res. 1977;47:331–336. [PubMed]
  • Watanabe AM, Chase TN, Cardon PV. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):740–746. [PubMed]
  • Leibowitz M, Lieberman A. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease. Neurology. 1975 Oct;25(10):917–921. [PubMed]
  • Poliomyelitis vaccines. Lancet. 1977 Jul 2;2(8027):21–22. [PubMed]
  • Agid Y, Pollak P, Bonnet AM, Signoret JL, Lhermitte F. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet. 1979 Mar 17;1(8116):570–572. [PubMed]
  • Teychenne PF, Leigh PN, Reid JL, Calne DB, Greenacre JK, Petrie A, Bamji AN. Idiopathic parkinsonism treated with bromocriptine. Lancet. 1975 Sep 13;2(7933):473–476. [PubMed]
  • Parkes JD, Debono AG, Marsden CD. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1101–1108. [PMC free article] [PubMed]
  • Agid Y, Barroche G, Bonnet AM, Javoy-Agid F, Kato G, Lhermitte F, Pollak P, Signoret JL. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease. Biomedicine. 1979 Jun;30(2):67–71. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group